
CSLLY
Healthcare · Biotechnology · $66.05B market cap
$34.41-0.26 (-0.7%)Nov 13, 3:58 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 10, 2026 | After the close | — | 0.82 | — |
| Aug 18, 2025 | After the close | — | 2.04 | — |
| Feb 10, 2025 | Time not confirmed | — | 4.13 | — |
| Jun 30, 2021 | Time not confirmed | 0.00 | 0.62 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | 0.62 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | 1.99 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | 1.99 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | 0.94 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | 0.94 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | 1.37 | — |
| Sep 30, 2019 | Time not confirmed | 0.00 | 1.37 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | 0.84 | — |
| Mar 31, 2019 | Time not confirmed | 0.00 | 0.84 | — |
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene…
| Dec 31, 2018 |
| Time not confirmed |
| 0.00 |
| 1.28 |
| — |
| Sep 30, 2018 | Time not confirmed | 0.00 | 1.27 | — |
| Jun 30, 2018 | Time not confirmed | 0.00 | 0.71 | — |
| Mar 31, 2018 | Time not confirmed | 0.00 | 0.71 | — |